Next Generation Cancer Diagnostics Market is estimated to be USD 42.0 billion by 2034 with a CAGR of 9.5% during the forecast period

NGS is arguably one of the most significant technological advances in biology in the last 30 years. Medical research has embraced technology because of the genetic nature of cancer, and the cancer sector is at the forefront of these efforts. New discoveries are likely to lead to new diagnostic, prognostic, and therapeutic targets as a result of global efforts to catalogue mutations in a range of cancer forms. NGS has advanced to the point where it is being considered for routine diagnostic use by some laboratories. In the research community, NGS has been widely employed for de novo genome sequencing, DNA resequencing, transcriptome sequencing, and epigenomics. These researches have led the way for the creation of new processes (both molecular and bioinformatic), as well as a deeper understanding of the technology's main advantages and disadvantages. Next Generation Cancer Diagnostics Market Size was valued at USD 18.4 billion in 2024 and is expected to grow at a CAGR of 9.5% to reach USD 42.0 billion by 2034.

The report " Next Generation Cancer Diagnostics Market, By Technology (RT-PCR, Next Generation Sequencing, DNA Microarray, Lab-on–a-chip and Others), By Cancer Type (Lung cancer, Prostate cancer, Breast cancer, Colorectal cancer and Others), By Application (CTC Analysis, Biomarker, Proteomic Analysis and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2034”

Key Highlights:

• In July 2021, Labcorp (NYSE: LH), a leading global life sciences company,  announced the availability of therascreen KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for treatment with LUMAKRAS™ (sotorasib), a new treatment option developed by Amgen.
• In July 2021, Labcorp (NYSE: LH), a leading global life sciences company, and OmniSeq, a CAP-accredited, molecular diagnostic innovation of Roswell Park Comprehensive Cancer Center, announced the launch of OmniSeq INSIGHT, a comprehensive genomic and immune profiling, tissue-based test that integrates next-generation sequencing (NGS) technology. The test is designed to advance precision oncology and improve patient outcomes, as part of Labcorp's commitment to empower better health decisions for patients through the addition of cutting-edge diagnostic tools in precision medicine.

Analyst View:

As the incidence of oncology problems develops, demand for next-generation cancer diagnostic tools is likely to rise. These tests are expected to aid in the early identification and accurate prognosis of a variety of cancers, positively impacting the vertical's growth over the projection period. The development and introduction of product offerings by a number of significant firms is expected to provide attractive growth opportunities for this industry. Many hospitals in impoverished countries are unable to invest in diagnostic imaging technology due to rising prices, decreasing reimbursement rates, and fiscal constraints. However, due to the rising demand for diagnostic imaging services in these nations, hospitals that cannot afford to buy new imaging equipment opt for used systems.

Key Market Insights from the report:

Next Generation Cancer Diagnostics Market is segmented based on the technology, cancer type, application and region.

• By Technology, the Next Generation Cancer Diagnostics Market is segmented into RT-PCR, Next Generation Sequencing, DNA Microarray, Lab-on–a-chip and Others.
• By Cancer Type, the market is segmented in Lung cancer, Prostate cancer, Breast cancer, Colorectal cancer and Others.
• By Application, the Next Generation Cancer Diagnostics Market is segmented into CTC Analysis, Biomarker, Proteomic Analysis and Others.
• By Region, the Next Generation Cancer Diagnostics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the Next Generation Cancer Diagnostics market. 

Get a Free Sample Copy of this Research Report: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4748

Competitive Landscape:

The key players operating in the Next Generation Cancer Diagnostics market includes Koninklijke Philips N.V., Illumina, Inc.,   F. Hoffmann-La Roche Ltd, Qiagen, Cepheid, Novartis AG, Abbott, Thermo Fisher Scientific, Inc., Sysmex Corporation Opko Health, Inc., Myriad Genetics, Inc., Agilent Technologies, GE Healthcare, PerkinElmer, Inc., Genomic Health, Inc., Hologic, Inc., Almac Group, Janssen Global Services, LLC, and Myriad Genetics.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.